重组人FSH联合重组人LH与单用重组人FSH在35-40岁女性辅助生殖技术中的有效性比较
基于德国IVF登记的真实世界数据,比较35-40岁女性辅助生殖技术中重组人FSH联合重组人LH(2:1比例)与单用重组人FSH的有效性。总体临床妊娠率和活产率两组无显著差异;在获卵5-14枚(作为正常卵巢储备的替代指标)女性的事后分析中,联合组的临床妊娠率和活产率显著更高,但未校正多重比较。
要点
- 总体人群临床妊娠率29.8% vs 27.8%、活产率20.3% vs 18.0%,两组无显著差异(P=0.269和P=0.092)。
- 获卵5-14枚女性事后分析中,联合组临床妊娠率33.1% vs 28.5%(P=0.001,未校正多重比较)。
- 获卵5-14枚女性事后分析中,联合组活产率22.5% vs 19.4%(P=0.014,未校正多重比较)。
核心结论
- 正常卵巢反应的高龄产妇(AMA)女性,重组人FSH联合重组人LH(2:1比例)较单用重组人FSH在活产率方面获益。
- 作者认为治疗有效性最好通过随机对照试验(RCT)评估,但真实世界数据对于评估生育治疗有效性有价值,尤其是临床试验中代表性不足的患者群体。
研究设计与样本
- 非干预性研究,使用德国IVF登记(Deutsches IVF-Register)的真实世界数据,比较重组人FSH联合重组人LH(2:1比例)与单用重组人FSH在35-40岁女性辅助生殖技术卵巢刺激中的有效性。
主要发现
- 总体临床妊娠率联合组29.8%(95%CI 28.2至31.6)vs 单用组27.8%(95%CI 26.5至29.2),无显著差异(P=0.269)。
- 总体活产率联合组20.3%(95%CI 18.7至21.8)vs 单用组18.0%(95%CI 16.6至19.4),无显著差异(P=0.092)。
- 获卵5-14枚女性事后分析中,临床妊娠率联合组33.1%(95%CI 31.0至35.0)vs 单用组28.5%(95%CI 26.6至30.4),P=0.001(未校正多重比较)。
- 获卵5-14枚女性事后分析中,活产率联合组22.5%(95%CI 20.5至24.2)vs 单用组19.4%(95%CI 17.6至20.9),P=0.014(未校正多重比较)。
临床怎么用
- 作者认为,正常卵巢反应的高龄产妇(AMA)女性,重组人FSH联合重组人LH(2:1比例)较单用重组人FSH在活产率方面获益。
- 作者认为治疗有效性最好通过随机对照试验(RCT)评估,但真实世界数据对于评估生育治疗有效性有价值,尤其是临床试验中代表性不足的患者群体。
局限性
- 获卵5-14枚女性的事后分析中,P=0.001和P=0.014均未校正多重比较。
- 作者认为治疗有效性最好通过随机对照试验(RCT)评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: According to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth? DESIGN: Non-interventional study comparing the effectiveness of r-hFSH and recombinant r-hLH (2:1 ratio) versus r-hFSH alone for ovarian stimulation during ART treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register. RESULTS: Overall clinical pregnancy (29.8%, 95% CI 28.2 to 31.6 versus 27.8%, 95% CI 26.5 to 29.2) and live birth (20.3%, 95% CI 18.7 to 21.8 versus 18.0%, 95% CI 16.6 to 19.4) rates were not significantly different between the combined r-hFSH and r-hLH group and the r-hFSH alone group (P = 0.269 and P = 0.092, respectively). Treatment effect was significantly higher for combined r-hFSH and r-hLH compared with r-hFSH alone for clinical pregnancy (33.1%, 95% CI 31.0 to 35.0 versus 28.5%, 95% CI 26.6 to 30.4; P = 0.001, not adjusted for multiplicity) and live birth (22.5%, 95% CI 20.5 to 24.2 versus 19.4%, 95% CI 17.6 to 20.9; P = 0.014, not adjusted for multiplicity) in a post-hoc analysis of women with five to 14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of combined r-hFSH and r-hLH for ovarian stimulation in women aged 35-40 years with normal ovarian reserve. CONCLUSIONS: Women of AMA with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials.
引用
- Bielfeld AP, Schwarze JE, Verpillat P, et al. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years. Reprod Biomed Online. 2023. PMID: 38593745. doi:10.1016/j.rbmo.2023.103725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。